Current
pharmacotherapy for
hypertrophic cardiomyopathy (HCM) is not disease-specific and has suboptimal efficacy, often necessitating interventional treatment. EXPLORER-HCM was a phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trial investigating the effects of
mavacamten, a first-in-class selective
cardiac myosin inhibitor, in patients with HCM,
left ventricular outflow tract obstruction (LVOTO) and New York Heart Association (NYHA) class II or III symptoms. The primary endpoint was defined as either a ≥1.5 ml/kg/min increase in peak oxygen consumption (pVO₂) and ≥1 NYHA class reduction or a ≥3.0 ml/kg/min pVO2 increase without NYHA class worsening. Secondary endpoints evaluated changes in post-exercise LVOT gradient, pVO2, NYHA class, Kansas City
Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS), and Hypertrophic Cardiomyopa-thy Symptom Questionnaire
Shortness-of-Breath subscore (HCMSQ-SoB). A total of 251 patients were randomized to receiving
mavacamten or placebo. The primary endpoint and all secondary endpoints were met significantly more frequently in the
mavacamten arm versus placebo. The safety profile of
mavacamten was similar to that of placebo. In conclusion, disease-specific treatment with
mavacamten in patients with obstructive HCM led to reduced LVOTO and improvement in both objective functional parameters and patient-related health status.